MARKET

VYGR

VYGR

Voyager
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.47
+0.06
+0.48%
Opening 13:33 07/14 EDT
OPEN
12.33
PREV CLOSE
12.41
HIGH
12.61
LOW
12.04
VOLUME
287.82K
TURNOVER
--
52 WEEK HIGH
26.03
52 WEEK LOW
6.26
MARKET CAP
463.77M
P/E (TTM)
-11.2130
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VYGR stock price target is 20.25 with a high estimate of 28.00 and a low estimate of 13.00.

EPS

VYGR News

More
ClearBridge Aggressive Growth Strategy Portfolio Manager Commentary Q2 2020
Seeking Alpha - Article · 2d ago
Annexon Initiates $100 Million IPO Effort
Seeking Alpha - Article · 3d ago
Homology Medicines (FIXX) Looks Good: Stock Adds 8% in Session
Zacks · 6d ago
Hedge Funds Are Selling Voyager Therapeutics, Inc. (VYGR)
Insider Monkey · 06/27 18:19
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
GuruFocus.com · 06/17 21:04
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 06/16 21:01
Is Now a Good Time To Buy Neurocrine Biosciences?
MotleyFool.com · 05/14 10:27
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
Barrons.com · 05/12 18:40

Industry

Biotechnology & Medical Research
+1.23%
Pharmaceuticals & Medical Research
+0.84%

Hot Stocks

Symbol
Price
%Change

About VYGR

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.
More

Webull offers kinds of Voyager Therapeutics Inc stock information, including NASDAQ:VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.